Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
ART involves taking a combination (usually three) of drugs daily, often combined into a single pill. ART has transformed the lives of people with HIV, enabling those with access to the medications to live a near-normal lifespan. Despite this success, the side effects, pill fatigue, stigma and expense of taking daily ART for life have motivated researchers to find an alternative, write NIAID Director Anthony S. Fauci, M.D., and colleagues.
Consequently, scientists are seeking ways to put HIV into full and sustained remission so daily ART is unnecessary. The authors say feasible approaches must involve minimal risk and manageable side effects for people with HIV and must be inexpensive and scalable to millions of individuals.
A major obstacle to sustained ART-free HIV remission is the persistence of viral reservoirs. These reservoirs consist of HIV-infected cells containing HIV genetic material that can generate new virus particles. The cells have entered a resting state that they maintain until they are activated to produce HIV.
The authors explain that two paths are being pursued toward sustained ART-free HIV remission: total eradication of the HIV reservoir, classically referred to as a "cure," and sustained virologic remission, which would control HIV replication but not eradicate the virus. The authors outline specific strategies under investigation to achieve these goals.
Several approaches to eradicating the HIV reservoir have been attempted, but none except stem cell transplantation from a donor with a specific genetic mutation has succeeded--and only in two cases. The risks, expense and complexity of stem cell transplants make them impractical for eradicating the HIV reservoir in people who do not require such a transplant for a separate underlying health condition, the authors write.
Many cutting-edge strategies to achieve sustained virologic remission are being studied. The authors describe how some of these strategies have the potential to replace daily ART with an intermittent or continual non-ART intervention, while others seek to induce permanent immune-mediated control of HIV without further intervention. Clinical trials of numerous different approaches are underway.
TW Chun et al. Durable control of HIV infection in the absence of antiretroviral therapy: opportunities and obstacles. JAMA DOI: 10.1001/jama.2019.5397 (2019)
NIAID Director Anthony S. Fauci, M.D., is available for comment.
To schedule interviews, please contact Laura S. Leifman, (301) 402-1663, email@example.com.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®
Laura S. Leifman | EurekAlert!
Scientists recreate blood-brain barrier defect outside the body
07.06.2019 | Cedars-Sinai Medical Center
Snout dated: Slow-evolving elephant shark offers new insights into human physiology
06.06.2019 | University of California - San Diego
Fraunhofer IZM is joining the EUROPRACTICE IC Service platform. Together, the partners are making fan-out wafer level packaging (FOWLP) for electronic devices available and affordable even in small batches – and thus of interest to research institutes, universities, and SMEs. Costs can be significantly reduced by up to ten customers implementing individual fan-out wafer level packaging for their ICs or other components on a multi-project wafer. The target group includes any organization that does not produce in large quantities, but requires prototypes.
Research always means trying things out and daring to do new things. Research institutes, universities, and SMEs do not produce in large batches, but rather...
A team led by scientists at the Department of Energy's Oak Ridge National Laboratory explored how atomically thin two-dimensional (2D) crystals can grow over 3D objects and how the curvature of those objects can stretch and strain the crystals. The findings, published in Science Advances, point to a strategy for engineering strain directly during the growth of atomically thin crystals to fabricate single photon emitters for quantum information processing.
The team first explored growth of the flat crystals on substrates patterned with sharp steps and trenches. Surprisingly, the crystals conformally grew up and...
In a study that combines experimental work and theoretical calculations made possible by supercomputers, scientists have determined the nuclear geometry of two...
The Fraunhofer Heinrich Hertz Institute HHI develops next-generation wireless transmission systems (Beyond 5G) based on Terahertz (THz) technologies. The THz technology supports significantly higher data transmission rates than current 4G and 5G mobile wireless technologies. Researchers of the department Photonic Networks and Systems, in collaboration with the Fraunhofer Institute for Applied Solid State Physics IAF, have succeeded in transmitting a 4K video in real-time over a wireless THz link. This was the first time this technology was successfully realized in a real-time experiment. A wireless transmission capacity of 100 Gbit/s was demonstrated over the THz link.
Requirements placed on transmission capacities in communication networks are continuously growing, driven by new applications such as Industry 4.0, autonomous...
Researchers from Sweden's Chalmers University of Technology and the University of Gothenburg present a new method which can double the energy of a proton beam produced by laser-based particle accelerators. The breakthrough could lead to more compact, cheaper equipment that could be useful for many applications, including proton therapy.
Proton therapy involves firing a beam of accelerated protons at cancerous tumours, killing them through irradiation. But the equipment needed is so large and...
29.04.2019 | Event News
17.04.2019 | Event News
15.04.2019 | Event News
07.06.2019 | Life Sciences
07.06.2019 | Life Sciences
06.06.2019 | Trade Fair News